Prescripción de antihipertensivos en personas con diabetes tipo 2 en Andalucía y recomendaciones SEH-LELHA 2022: evaluación del coste y uso

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular Pub Date : 2024-10-01 DOI:10.1016/j.hipert.2024.06.004

D. Martín-Enguix , J.C. Aguirre Rodríguez , M. Guisasola Cárdenas , M.N. Generoso Torres , A. Hidalgo Rodríguez , M. Sánchez Cambronero , A. González Bravo

{"title":"Prescripción de antihipertensivos en personas con diabetes tipo 2 en Andalucía y recomendaciones SEH-LELHA 2022: evaluación del coste y uso","authors":"D. Martín-Enguix , J.C. Aguirre Rodríguez , M. Guisasola Cárdenas , M.N. Generoso Torres , A. Hidalgo Rodríguez , M. Sánchez Cambronero , A. González Bravo","doi":"10.1016/j.hipert.2024.06.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to analyze the prescription of antihypertensive drugs in patients with type 2 diabetes (T2D) in Andalusia, comparing it with the SEH-LELHA 2022 guidelines, and to assess the direct cost of these treatments.</div></div><div><h3>Materials and methods</h3><div>A multicentric, cross-sectional, and descriptive study was conducted with 385 T2D patients. Participants were randomly selected from the patient lists of 120 primary care physicians from Andalusia. Inclusion criteria included a diagnosis of T2D and complete clinical records for the year 2022. Demographic data and drug prescription information were collected, with the average cost per patient being calculated.</div></div><div><h3>Results</h3><div>The mean age of the subjects was 70.72 years, with 53.51% being male. A total of 70.9% of the patients were taking antihypertensive drugs, the most common being ACE inhibitors/ARBs (70.9%), diuretics (70.1%), beta-blockers (40.0%), and calcium channel blockers (20.0%). Each patient took an average of 2.46±1.06 antihypertendsive, and fixed association of 2 or more antihypertensive drugs were used by 40.9% of the studied patients. The annual cost per patient was 141.45€/year.</div></div><div><h3>Conclusions</h3><div>The study reveals strong adherence to the SEH-LELHA 2022 guidelines among physicians in Andalusia regarding the of antihypertensives for T2D patients, with a significant preference for Renin-Angiotensin System blockers, diuretics, and beta-blockers. However, a notable deviation in prescription practices was observed with the frequent choice of doxazosin over spironolactone, despite the latter being the recommended option for resistant hypertension. Although the overall expenditure on antihypertensives is moderate, their cost-effectiveness is enhanced by the efficacy of these treatments in preventing cardiovascular complications.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 4","pages":"Pages 226-231"},"PeriodicalIF":1.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183724000837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aims to analyze the prescription of antihypertensive drugs in patients with type 2 diabetes (T2D) in Andalusia, comparing it with the SEH-LELHA 2022 guidelines, and to assess the direct cost of these treatments.

Materials and methods

A multicentric, cross-sectional, and descriptive study was conducted with 385 T2D patients. Participants were randomly selected from the patient lists of 120 primary care physicians from Andalusia. Inclusion criteria included a diagnosis of T2D and complete clinical records for the year 2022. Demographic data and drug prescription information were collected, with the average cost per patient being calculated.

Results

The mean age of the subjects was 70.72 years, with 53.51% being male. A total of 70.9% of the patients were taking antihypertensive drugs, the most common being ACE inhibitors/ARBs (70.9%), diuretics (70.1%), beta-blockers (40.0%), and calcium channel blockers (20.0%). Each patient took an average of 2.46 ± 1.06 antihypertendsive, and fixed association of 2 or more antihypertensive drugs were used by 40.9% of the studied patients. The annual cost per patient was 141.45 €/year.

Conclusions

The study reveals strong adherence to the SEH-LELHA 2022 guidelines among physicians in Andalusia regarding the of antihypertensives for T2D patients, with a significant preference for Renin-Angiotensin System blockers, diuretics, and beta-blockers. However, a notable deviation in prescription practices was observed with the frequent choice of doxazosin over spironolactone, despite the latter being the recommended option for resistant hypertension. Although the overall expenditure on antihypertensives is moderate, their cost-effectiveness is enhanced by the efficacy of these treatments in preventing cardiovascular complications.

查看原文本刊更多论文

[安达卢西亚 2 型糖尿病患者的抗高血压处方与 SEH-LELHA 2022 准则：经济成本评估]。

研究目的本研究旨在分析安达卢西亚地区 2 型糖尿病（T2D）患者的降压药处方，将其与 SEH-LELHA 2022 指南进行比较，并评估这些治疗的直接成本：对 385 名 T2D 患者进行了多中心、横断面和描述性研究。参与者从安达卢西亚 120 名初级保健医生的患者名单中随机抽取。纳入标准包括 T2D 诊断和 2022 年的完整临床记录。研究人员收集了人口统计学数据和药物处方信息，并计算了每位患者的平均费用：研究对象的平均年龄为 70.72 岁，男性占 53.51%。共有 70.9% 的患者正在服用降压药，其中最常见的是 ACE 抑制剂/ARB（70.9%）、利尿剂（70.1%）、β-受体阻滞剂（40.0%）和钙通道阻滞剂（20.0%）。每位患者平均服用 2.46±1.06 种降压药，40.9% 的研究对象使用 2 种或 2 种以上降压药的固定组合。每位患者每年的费用为 141.45 欧元/年：这项研究表明，安达卢西亚的医生在为 T2D 患者使用降压药时非常遵守 SEH-LELHA 2022 指南，并明显偏爱肾素-血管紧张素系统阻滞剂、利尿剂和β-受体阻滞剂。然而，处方做法出现了明显的偏差，经常选择多沙唑嗪而不是螺内酯，尽管后者是治疗抵抗性高血压的推荐选择。虽然抗高血压药物的总体支出不高，但这些治疗方法在预防心血管并发症方面的功效提高了其成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hipertension y Riesgo Vascular Medicine-Internal Medicine

CiteScore

1.70

自引率

16.70%

发文量

审稿时长

39 days

期刊介绍： La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.